scout
|Videos|July 18, 2014

Immunotherapy Combination Strategies in RCC

For High-Definition, Click

Immunotherapy combination strategies in renal cell carcinoma could be hampered by toxicity concerns, believes Brian I. Rini, MD. The need for combination approaches with a PD-1 inhibitor and a CTLA-4 inhibitor should be personalized based on patient characteristics. However, deciding which patient should receive a combination versus a single-agent remains to be seen.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME